Tranexamic Acid Is Not Associated With a Change in Infection Risk in Trauma Patients.

Introduction: Tranexamic acid (TXA) has been used as an adjunct in traumatic hemorrhage management. Outside of trauma, TXA has been used to limit blood loss across multiple surgical fields. TXA has also been found to have an immune-modulating effect, reducing postoperative infection rates. However, the relationship between TXA and infection rates in trauma patients is unclear.

Methods: We performed a single-institution retrospective cohort analysis of 364 trauma patients who underwent massive transfusion protocol activation at a level-one trauma level center over a 7-y period. Patients were placed into two groups based on TXA administration (No TXA and TXA). Minors, patients on anticoagulants, pregnant patients, and those who died upon arrival or were hospitalized for less than 1 d were excluded. Univariate and multivariate analysis with propensity score matching were used to evaluate the association between TXA and infection rates.

Results: Sixty-one patients (16.8%) received TXA, and 303 patients (83.2%) did not. TXA was associated with an increased risk of infection on univariate analysis (P = 0.007). However, on multivariate analysis after propensity score matching, TXA was not associated with infection (P = 0.975) while total hospital days and total ventilator days were associated with an increased risk of infection (P = 0.012, P = 0.014).

Conclusions: Our study found no association between TXA and infection rates among our patient cohort. While TXA remains an important adjunct in trauma resuscitation, we did not find an association between TXA and infection in trauma patients.